// App-Quantinova.ai

POS0226 (2021) : BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

Researchers

Presenter

  • D. Van der Heijde

Principal Investigators

  • A. Deodhar

  • L. S. Gensler

  • D. Poddubnyy

  • A. Kivitz

  • M. Dougados

  • N. De Peyrecave

  • M. Oortgiesen

  • T. Vaux

  • C. Fleurinck

  • X. Baraliakos

Medical Centers

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

  • Charite Universitatsmedizin Berlin, Department of Gynecology, Berlin, Germany

  • Altoona Center for Clinical Research, Altoona Arthritis & Osteoporosis Center, Duncansville, PA, United States of America

  • APHP Hopital Cochin Department of Dermatology, Paris, France

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Raleigh, United States of America

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

Locations

  • Netherlands

  • United States

  • Germany

  • France

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02963506

  • NCT03355573

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved